[1] |
CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun.
48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798.
|
[2] |
SHEN Lu, LIU Cuili, WANG Yi, HAO Mingqiang, WANG Yali, ZHU Huijuan, WU Chen, YANG Yang.
Precision Pharmacovigilance for Cell and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 633-639.
|
[3] |
XIE Ziyue, WANG Chengxiang, HU Yanpeng, LI Lei, CUI Herong.
Clinical Medications and Safety Analysis of Traditional Chinese Medicine for Post-Infection Cough
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 507-512.
|
[4] |
WANG Jiaqing, WANG Qi, LIU Tongtong, ZHANG Dongjie, CHEN Qi, MEI Shenghui, NING Xiao.
Determination of Linezolid Concentrations in Plasma with HPLC-MS/MS Method
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 377-380.
|
[5] |
LAN Xiaoqian, GUO Wei.
Trough Steady-State Concentration/Dose Ratio and Contributors to Adverse Drug Reactions of Sulpiride
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 420-423.
|
[6] |
WANG Han, WANG Cunxuan, LYU Xuehaiyue, ZHANG Lining, SUO Yusi, GU Zhi'en, WANG Ping, JIN Xuejing.
Chinese Patent Medicines for Preventing Myelosuppression in Adjuvant Treatment of Malignant Tumors: a Systematic Review and Network Meta-Analysis
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 169-176.
|
[7] |
CAO Yin, ZHOU Xuan, DAI Biao, DENG Yiyun, YAN Chunyu, SHAN Feng, XIA Qingrong, LIANG Jun.
A UPLC-MS/MS method for determination of human serum trazodone concentration and its clinical individualized medications
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 991-997.
|
[8] |
LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming.
Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
|
[9] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
[10] |
ZHANG Caixia, ZHOU Yi, TAN Lu, CHEN Wenming, LIU Yang, YOU Yu.
Pharmaceutical care of pulmonary aspergillus infection secondary to sepsis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1064-1067.
|
[11] |
ZHANG Qian, YUN Yuan, HE Lian.
Pharmaceutical care of hyperprolactinemia in a patient induced by risperidone
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 936-938.
|
[12] |
WANG Dan, DONG Duo, TIAN Chunhua.
Course of development of pharmocovigilance systems in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 735-740.
|
[13] |
CHENG Yijing, LI Tao, LIU Junting, HUANG Guimin, ZHONG Xuli, LIN Aihua, PAN Shoudong, LI Long, BAI Dongsheng, ZHAN Xiaojun, LIU Zhenjiang, REN Wei, NIE Xiaolu, TAI Jun.
Safety evaluation of haemocoagulase agkistrodon for injection in children based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 787-790.
|
[14] |
LIU Yan, AN Jing, JIAO Yongzhuo, LIANG Xuefeng, ZHANG Xiaoshu.
Simple febrile seizures within 30 days of vaccination with the measles, mumps and rubella combined attenuated live vaccine in U-12 children in the real world
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 805-810.
|
[15] |
ZHAO Xuan, ZHENG Tingting, LI Xuemei, MAO Lu, GUO Jing, ZHANG Wei.
Adverse reaction reports of vancomycin in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 811-815.
|